



Docket No.: 022290.0120PTUS
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Catherine Castan et al.

Application No.: 10/510,643

Confirmation No.: 1869

Filed: May 23, 2005

Art Unit: 1615

For: ORAL PHARMACEUTICAL
FORMULATION IN THE FORM OF AN
AQUEOUS SUSPENSION FOR THE
MODIFIED RELEASE OF ACTIVE
PRINCIPLE(S)

Examiner: C. E. Helm

INFORMATION DISCLOSURE STATEMENT (IDS)

MS RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be considered for this application.

This Supplemental Information Disclosure Statement, pursuant to 37 CFR 1.114(c), accompanies the Request for Continued Examination (37 CFR 1.114) submitted concurrently.

In accordance with 37 CFR § 1.98(a)(2)(ii), Applicants have not submitted copies of U.S. patents and U.S. patent applications. Similarly, copies of Office Actions issued in commonly-owned U.S. patent applications directed to similar subject matter, also stored and available to the Examiner in electronic form in the Office's IFW system, have not been submitted. 69 FR 56481, 56510, Sept. 21, 2004. In accordance with 37 CFR 1.98(a)(2)(ii), Applicants have not submitted copies of U.S. patents and U.S. patent applications. Applicants submit herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).


In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Supplemental Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Applicants submit concurrently a Request for Continued Examination pursuant to 37 C.F.R. § 1.114, and the accompanying fees. Please charge our Credit Card in the amount of \$810.00 covering the fees set forth in 37 C.F.R. § 1.17(e). The U.S. Patent and Trademark Office is authorized to charge any additional fees that may be required in conjunction with this submission to Deposit Account Number 50-2228, under Order No. 022290.0120PTUS.

Dated: September 25, 2009

Respectfully submitted,

By 

Lacy L. Kolo

Registration No.: 55,340

PATTON BOGGS LLP

8484 Westpark Drive, 9th Floor

McLean, Virginia 22102

(703) 744-8029

(703) 744-8001 (Fax)

Attorney for Applicants